Merck KGaA Strengthens Synthetic Lethality Pipeline with US$6.9 B Artios Alliance
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)
Published: 10 Dec-2020
DOI: 10.3833/pdr.v2020.i12.2577 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to bolster its oncology portfolio, Merck KGaA has entered into a three-year collaboration with Artios Pharma to discover and develop precision oncology candidates for up to eight targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS